Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients

Kidney International Supplements

Volumn 2, Issue 5, 2012, Pages 347-356

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84978869525     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.52     Document Type: Article

References (114)

1. National Kidney Foundation, K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (2004), S1–S290.
2. National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002), S1–S266.
3. Levin, N.W., Kotanko, P., Eckardt, K.U., et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 77 (2010), 273–284.
4. Chobanian, A.V., Bakris, G.L., Black, H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
5. Agarwal, R., Andersen, M.J., Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int 69 (2006), 406–411.
6. Andersen, M.J., Khawandi, W., Agarwal, R., Home blood pressure monitoring in CKD. Am J Kidney Dis 45 (2005), 994–1001.
7. Ahmed, A.K., Kamath, N.S., El Kossi, M., et al. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25 (2010), 3977–3982.
8. National Kidney Foundation, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (2007), S1–S179.
9. Acelajado, M.C., Oparil, S., Hypertension in the elderly. Clin Geriatr Med 25 (2009), 391–412.
10. Covic, A., Gusbeth-Tatomir, P., Goldsmith, D.J., Arterial stiffness in renal patients: an update. Am J Kidney Dis 45 (2005), 965–977.
11. London, G.M., Guerin, A.P., Verbeke, F.H., et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18 (2007), 613–620.
12. Ohya, Y., Iseki, K., Iseki, C., et al. Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort. Am J Kidney Dis 47 (2006), 790–797.
13. Pannier, B., Guerin, A.P., Marchais, S.J., et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 45 (2005), 592–596.
14. Toussaint, N.D., Lau, K.K., Strauss, B.J., et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23 (2008), 586–593.
15. Cockcroft, J.R., Wilkinson, I.B., Evans, M., et al. Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am J Hypertens 18 (2005), 1463–1467 discussion 1468–1469.
16. Domanski, M.J., Davis, B.R., Pfeffer, M.A., et al. Isolated systolic hypertension : prognostic information provided by pulse pressure. Hypertension 34 (1999), 375–380.
17. Schram, M.T., Kostense, P.J., Van Dijk, R.A., et al. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens 20 (2002), 1743–1751.
18. Messerli, F.H., Mancia, G., Conti, C.R., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006), 884–893.
19. Somes, G.W., Pahor, M., Shorr, R.I., et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 159 (1999), 2004–2009.
20. Denardo, S.J., Gong, Y., Nichols, W.W., et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med 123 (2010), 719–726.
21. Oates, D.J., Berlowitz, D.R., Glickman, M.E., et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 55 (2007), 383–388.
22. Benvenuto, L.J., Krakoff, L.R., Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens 24 (2011), 135–144.
23. Wu, J.S., Yang, Y.C., Lu, F.H., et al. Population-based study on the prevalence and correlates of orthostatic hypotension/hypertension and orthostatic dizziness. Hypertens Res 31 (2008), 897–904.
24. Alderman, M.H., Salt, blood pressure, and human health. Hypertension 36 (2000), 890–893.
25. Jones, D.W., Kim, J.S., Andrew, M.E., et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 12 (1994), 1433–1437.
26. Whelton, S.P., Chin, A., Xin, X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 136 (2002), 493–503.
27. Chen, L., Davey Smith, G., Harbord, R.M., et al. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med, 5, 2008, e52.
28. Brown, C.D., Higgins, M., Donato, K.A., et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8 (2000), 605–619.
29. The Obesity in Asia Collaboration, Is central obesity a better discriminator of the risk of hypertension than body mass index in ethnically diverse populations?. J Hypertens 26 (2008), 169–177.
30. Whitlock, G., Lewington, S., Sherliker, P., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373 (2009), 1083–1096.
31. Dickinson, H.O., Mason, J.M., Nicolson, D.J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24 (2006), 215–233.
32. Navaneethan, S.D., Yehnert, H., Moustarah, F., et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4 (2009), 1565–1574.
33. Buchwald, H., Estok, R., Fahrbach, K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122 (2009), 248–256 e245.
34. James, W.P., Caterson, I.D., Coutinho, W., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363 (2010), 905–917.
35. Topol, E.J., Bousser, M.G., Fox, K.A., et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376 (2010), 517–523.
36. Kalantar-Zadeh, K., Abbott, K.C., Salahudeen, A.K., et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 81 (2005), 543–554.
37. Pifer, T.B., McCullough, K.P., Port, F.K., et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 62 (2002), 2238–2245.
38. Hoogeveen, E.K., Halbesma, N., Rothman, K.J., et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 7 (2012), 280–288.
39. World Health Organization, Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk, 2007.
40. Hooper, L., Bartlett, C., Davey Smith, G., et al. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ, 325, 2002, 628.
41. Esnault, V.L., Ekhlas, A., Delcroix, C., et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 16 (2005), 474–481.
42. Phillips, C.O., Kashani, A., Ko, D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167 (2007), 1930–1936.
43. Slagman, M.C., Waanders, F., Hemmelder, M.H., et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ, 343, 2011, d4366.
44. Vogt, L., Waanders, F., Boomsma, F., et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19 (2008), 999–1007.
45. Ekinci, E.I., Clarke, S., Thomas, M.C., et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care 34 (2011), 703–709.
46. Thomas, M.C., Moran, J., Forsblom, C., et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 34 (2011), 861–866.
47. Chen, J.L., Lerner, D., Ruthazer, R., et al. Association of physical activity with mortality in chronic kidney disease. J Nephrol 21 (2008), 243–252.
48. O'Hare, A.M., Tawney, K., Bacchetti, P., et al. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 41 (2003), 447–454.
49. Stack, A.G., Molony, D.A., Rives, T., et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 45 (2005), 690–701.
50. World Health Organization, International Guide for Monitoring Alcohol Consumption and Related Harm, 2000.
51. Jee, S.H., Miller, E.R., Guallar, E., et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 15 (2002), 691–696.
52. Campbell, F., Dickinson, H.O., Critchley, J.A., et al. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol, 2012 in press.
53. Donadio, J.V., Bergstralh, E.J., Offord, K.P., et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 331 (1994), 1194–1199.
54. Swan, S.K., Olyaei, A., Sica, D., Clinical pharmacology for the nephrologist. NephSap 9 (2010), 220–264.
55. Agarwal, R., Andersen, M.J., Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am J Nephrol 26 (2006), 503–510.
56. Davidson, M.B., Hix, J.K., Vidt, D.G., et al. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 166 (2006), 846–852.
57. Minutolo, R., Agarwal, R., Borrelli, S., et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 171 (2011), 1090–1098.
58. Hermida, R.C., Ayala, D.E., Mojon, A., et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 27 (2010), 1629–1651.
59. Hermida, R.C., Ayala, D.E., Mojon, A., et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 58 (2011), 1165–1173.
60. Hermida, R.C., Ayala, D.E., Mojon, A., et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 22 (2011), 2313–2321.
61. Gupta, A.K., Arshad, S., Poulter, N.R., Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55 (2010), 399–407.
62. US Food and Drug Administration, Public health advisory: Angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053113.htm accessed 2 July 2012.
63. Barreras, A., Gurk-Turner, C., Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 16 (2003), 123–126.
64. Matchar, D.B., McCrory, D.C., Orlando, L.A., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148 (2008), 16–29.
65. Holtkamp, F.A., de Zeeuw, D., Thomas, M.C., et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80 (2011), 282–287.
66. Weir, M.R., Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?. Kidney Int 80 (2011), 235–237.
67. Bomback, A.S., Klemmer, P.J., The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3 (2007), 486–492.
68. Palmer, B.F., Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347 (2002), 1256–1261.
69. Bridoux, F., Hazzan, M., Pallot, J.L., et al. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 7 (1992), 100–104.
70. Kohli, H.S., Bhaskaran, M.C., Muthukumar, T., et al. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant 15 (2000), 212–217.
71. Wynckel, A., Ebikili, B., Melin, J.P., et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am J Hypertens 11 (1998), 1080–1086.
72. Adhiyaman, V., Asghar, M., Oke, A., et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 94 (2001), 512–514.
73. Loboz, K.K., Shenfield, G.M., Drug combinations and impaired renal function -- the ‘triple whammy’. Br J Clin Pharmacol 59 (2005), 239–243.
74. Jafar, T.H., Stark, P.C., Schmid, C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003), 244–252.
75. Balamuthusamy, S., Srinivasan, L., Verma, M., et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 155 (2008), 791–805.
76. Oregon Health Resources Commission, Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers Draft, January, 2010.
77. Oregon Health Resources Commission, Angiotensin-Converting Enzyme Inhibitors (ACEIs) Subcommittee Report Update, July, 2005.
78. Oregon Health Resources Commission, Angiotensin II Receptor Antagonists (AIIRA) Subcommittee Report, March, 2006.
79. Bakris, G.L., Sarafidis, P.A., Weir, M.R., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375 (2010), 1173–1181.
80. Batterink, J., Stabler, S.N., Tejani, A.M., et al. Spironolactone for hypertension. Cochrane Database Syst Rev, 2010, CD008169.
81. Becker, G.J., Hewitson, T.D., Chrysostomou, A., Aldosterone in clinical nephrology--old hormone, new questions. Nephrol Dial Transplant 24 (2009), 2316–2321.
82. Epstein, M., Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37 (2001), 677–688.
83. Goodfriend, T.L., Treating resistant hypertension with a neglected old drug. Hypertension 49 (2007), 763–764.
84. Epstein, M., Williams, G.H., Weinberger, M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006), 940–951.
85. Bomback, A.S., Kshirsagar, A.V., Amamoo, M.A., et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51 (2008), 199–211.
86. Mehdi, U.F., Adams-Huet, B., Raskin, P., et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20 (2009), 2641–2650.
87. Bianchi, S., Bigazzi, R., Campese, V.M., Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70 (2006), 2116–2123.
88. Toto, R.D., Aldosterone blockade in chronic kidney disease: can it improve outcome?. Curr Opin Nephrol Hypertens 19 (2010), 444–449.
89. Rebello, S., Compain, S., Feng, A., et al. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol 51 (2011), 1549–1560.
90. Parving, H.H., Persson, F., Lewis, J.B., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008), 2433–2446.
91. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24 (2009), 1663–1671.
92. US Food and Drug Administration, FDA drug safety communication: New warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm.
93. Ernst, M.E., Moser, M., Use of diuretics in patients with hypertension. N Engl J Med 361 (2009), 2153–2164.
94. Bakris, G., Molitch, M., Hewkin, A., et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29 (2006), 2592–2597.
95. National Clinical Guideline Center, Hypertension. The Clinical Management of Primary Hypertension in Adults. Clinical Guideline 127, 2011, Commissioned by the National Institute for Health and Clinical Excellence.
96. Gallagher, M., Perkovic, V., Chalmers, J., Diuretics: a modern day treatment option?. Nephrology (Carlton) 11 (2006), 419–427.
97. Duarte, J.D., Cooper-DeHoff, R.M., Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 8 (2010), 793–802.
98. Dussol, B., Moussi-Frances, J., Morange, S., et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 20 (2005), 349–353.
99. Musini, V.M., Wright, J.M., Bassett, K., et al. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev, 2009, CD003825.
100. Bakris, G., An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 53 (2009), 379–387.
101. Frishman, W.H., Alwarshetty, M., Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. Clin Pharmacokinet 41 (2002), 505–516.
102. Ram, C.V., Beta-blockers in hypertension. Am J Cardiol 106 (2010), 1819–1825.
103. Oregon Health Resources Commission, Beta Adrenergic Blockers Pharmaceutical Subcommittee Report. Update #3, March 2008.
104. Badve, S.V., Roberts, M.A., Hawley, C.M., et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 58 (2011), 1152–1161.
105. Chen, J.M., Heran, B.S., Perez, M.I., et al. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension. Cochrane Database Syst Rev, 2010, CD007185.
106. Ritz, E., Rump, L.C., Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?. Curr Hypertens Rep 9 (2007), 409–414.
107. Sica, D.A., Gehr, T.W., Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. Curr Opin Nephrol Hypertens 12 (2003), 123–131.
108. Bakris, G.L., Weir, M.R., Secic, M., et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 65 (2004), 1991–2002.
109. Oregon Health Resources Commission, Calcium Channel Blocker Subcommittee Report Update #2. 2005 May.
110. Hart, P., Bakris, G.L., Calcium antagonists: Do they equally protect against kidney injury?. Kidney Int 73 (2008), 795–796.
111. Fenton, C., Keating, G.M., Lyseng-Williamson, K.A., Moxonidine: a review of its use in essential hypertension. Drugs 66 (2006), 477–496.
112. Sica, D.A., Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 9 (2007), 399–405.
113. Vonend, O., Marsalek, P., Russ, H., et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 21 (2003), 1709–1717.
114. Cohn, J.N., Pfeffer, M.A., Rouleau, J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003), 659–667.